form_15.htm
OMB
APPROVAL
|
OMB
Number: 3235-0167
Expires: November
30, 2010
Estimated
average burden
hours
per response . . . . . 1.50
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
15
CERTIFICATION
AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission
File Number: 000-14879
Cytogen
Corporation
(Exact
name of registrant as specified in its charter)
650
College Road East, Suite 3100, Princeton, New Jersey 08540, (609)
750-8200
(Address,
including zip code, and telephone number, including area code, of registrant’s
principal executive offices)
Common
Stock, $0.01 par value
(Title of
each class of securities covered by this Form)
None
(Titles
of all other classes of securities for which a duty to file reports under
section 13(a) or 15(d) remains)
Please
place an X in the box(es) to designate the appropriate rule provision(s) relied
upon to terminate or suspend the duty to file reports:
Rule
12g-4(a)(1)(i)*
|
ý
|
|
Rule
12h-3(b)(1)(i)
|
ý
|
Rule
12g-4(a)(1)(ii)
|
£
|
|
Rule
12h-3(b)(1)(ii)
|
£
|
Rule
12g-4(a)(2)(i)
|
£
|
|
Rule
12h-3(b)(2)(i)
|
£
|
Rule
12g-4(a)(2)(ii)
|
£
|
|
Rule
12h-3(b)(2)(ii)
|
£
|
|
|
|
Rule
15d-6
|
£
|
* The
registrant is relying upon current Rule 12g-4(a)(1) to terminate the duty to
file reports.
Approximate number of holders of record
as of the certification or notice date:**
One
**All of
the shares of Common Stock, $0.01 par value, of the registrant were purchased by
EUSA Pharma, Inc., in connection with the merger of EUSA Pharma (USA), Inc, a
wholly-owned subsidiary of EUSA Pharma, Inc., with and into the registrant,
which became effective as of May 8, 2008.
Pursuant
to the requirements of the Securities Exchange Act of 1934 Cytogen Corporation
has caused this certification/notice to be signed on its behalf by the
undersigned duly authorized person.**
Date: May 9,
2008 By: /s/ KEVIN G. LOKAY
Name: Kevin
G. Lokay
Title: President
and Chief Executive Officer
Persons who respond
to the collection of information contained
in this form
are not required to respond unless the form displays
SEC 2069
(12-04) a currently valid
OMB control number.